Clinical Research

Ongoing Clinical Trials

We have dedicated years to researching the safety and efficacy of MSCs for therapeutic use and have produced MSCs for over 9,000 therapies without incurring any adverse events.

Our ability to produce billions of identical and genetically stable MSCs, our unique network of certified administering physicians and our positive, collaborative relationships with the U.S. FDA and COFEPRIS (Mexico’s equivalent to the FDA) make us a leader in the stem cell sector.

View the Clinical Trials

Leading the Way in Stem Cell Banking & Therapy

About Celltex Therapeutics

We are the nation’s leading commercial autologous (your own) adipose (fat)-derived MSC cryopreservation company and focus on spearheading breakthroughs in regenerative medicine using MSCs.

We also produce specialized allogeneic (donor) MSCs for use in clinical trials. Currently, Celltex has nine ongoing clinical trials in two countries and one major partnership study with Texas A&M University.

The Celltex Difference

How It Works

We use our own proprietary technology to isolate, cryopreserve and culture hundreds of millions of identical and genetically stable MSCs in our state-of-the-art, current Good Manufacturing Practices (cGMP)-compliant laboratory.

Celltex-produced MSCs are used in a range of therapies including immune system support, severe COVID-19 symptoms, injuries and chronic pain, as well as for many other conditions, including vascular, autoimmune and degenerative diseases, such as multiple sclerosis, severe arthritis, Parkinson’s disease and Alzheimer’s disease.

Clinical Trials in the U.S.

In the U.S., the following clinical trials are in progress:


Phase II

Phase II clinical trial utilizing autologous MSCs as a prophylactic (preventative) medicine for individuals at high risk of contracting COVID-19.

Learn More

Severe COVID-19 Symptoms

Phase II

Phase II clinical trial utilizing allogeneic MSCs as a treatment for individuals with severe COVID-19 symptoms.

Rheumatoid Arthritis

Phase I/IIa

Phase I/IIa clinical trial utilizing autologous MSCs for Rheumatoid arthritis.

Learn More


Phase II

Phase II clinical trial utilizing autologous MSCs for osteoarthritis.

Learn More

Alzheimer’s Disease

Texas A&M University Partnership

Major partnership study with Texas A&M University IRM using proprietary A-1™ Exosomes for treatment of Alzheimer’s disease.

Clinical Trials in Mexico

In Mexico, the following clinical trials are in progress:

Rheumatoid Arthritis, Osteoarthritis & Secondary Conditions

Phase IIb

Phase IIb clinical trial utiling autologous MSCs for Rheumatoid arthritis and Osteoarthritis, as well as secondary conditions and diseases that cause a deterioration of quality of life, is more than half-way completed with excellent results so far.

This trial is being conducted at Hospital Galenia, a private hospital in Cancun.

Severe COVID-19 Symptoms

Phase I

Phase I clinical trial utilizing allogeneic MSCs as adjuvent treatment for severe COVID-19 symptoms is in the COFEPRIS review process.

Clinical Research

Committed to Leading the Future of Regenerative Medicine

Our industry leadership and visionary approach continue to drive us to improve the quality of life of thousands of individuals, with a concerted focus to make this therapy accessible to all in the near future.



View Client Stories

MSCs produced by Celltex have been credited with results that have shifted a person’s multi-drug dependency to one’s own stem cells. Up to eighty percent (80%) of Celltex clients report improvements in at least one symptom area for which they received therapy using Celltex-produced MSCs.

Hear personal stories from real clients about how they found a better quality of life through Celltex.

Email Icon

News & Information

Stay in the know about Celltex

Sign up to receive news, announcements, updates and offers about the latest happenings at Celltex.

I consent to the transfer and validation of my email address in conjunction with this email service, and I understand that I may withdraw my consent and unsubscribe at any time.